Internationally health economic evaluations are a fixed component of reimbursement decisions, says IQWiG

17 November 2014

Internationally health economic evaluations (HEEs) form a legally regulated fixed component in health-care decisions. This applies particularly to the drug sector.

While HEEs are never directly implemented on a 1:1 basis in reimbursement regulations, they create transparency for all stakeholders in the system. These are some of the results presented in the journal issue, which was guest-edited by the German Institute for Quality and Efficiency in Health Care (IQWiG) and compiled contributions on the experience with HEE in seven countries.

Choice of countries allows for a multidimensional comparison

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical